Arch Biopartners Provides Update on AB569 Progress

Biotech Investing

Arch Biopartners announced the good manufacturing practice production campaign for AB569 has advanced to the GMP glass vial filling stage.

Arch Biopartners (TSXV:ARCH; OTCBB:ACHFF) announced the good manufacturing practice (GMP) production campaign for AB569 has advanced to the GMP glass vial filling stage.
As quoted in the press release:

AB569 is the Company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients as well as many other indications.
AB569 is a potential stand alone or complementary treatment to existing and emerging standard of care therapies for CF and COPD patients that have reduced lung function due to multi-drug resistant bacterial infections.

Click here to read the full press release.

Source: www.marketwired.com

antibiotic-resistant bacterial infections arch biopartners copd cystic fibrosis disease drug candidate manufacturing patients Biotech Investing